Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diphtheria toxoid T-cell epitopes are specific peptide fragments derived from the inactivated toxin of Corynebacterium diphtheriae that serve as potent stimulators of the adaptive immune system. These epitopes are primarily recognized by CD4+ T-helper cells when presented by Major Histocompatibility Complex (MHC) class II molecules on the surface of antigen-presenting cells (APCs) (Diethelm-Okita et al., 2000). Their biological significance lies in their ability to provide 'T-cell help,' which is essential for B-cell maturation and the production of high-affinity IgG antibodies (StatPearls, 2023). In the context of vaccinology, these epitopes are often utilized within carrier proteins like CRM197 to enhance the immunogenicity of polysaccharide antigens, which are otherwise poorly recognized by T cells (FDA, 2023). This mechanism allows for the development of effective conjugate vaccines against pathogens such as Streptococcus pneumoniae and Neisseria meningitidis. Clinically, the presence and recognition of these epitopes are monitored through antibody titers and cellular immune assays to ensure vaccine efficacy. While generally safe, exposure to these epitopes can occasionally trigger hypersensitivity reactions in sensitized individuals (CDC, 2022).
Diphtheria toxoid T-cell epitopes are processed by professional antigen-presenting cells (APCs) and displayed on the cell surface via Major Histocompatibility Complex (MHC) class II molecules. These peptide-MHC complexes are recognized by the T-cell receptors (TCRs) of naive or memory CD4+ T-helper cells, leading to their activation, proliferation, and secretion of cytokines such as IL-4 and IL-2. This T-cell help is crucial for B-cell activation, isotype switching, and the generation of high-affinity antibodies against the toxoid or any conjugated polysaccharide antigens.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diphtheria toxoid T-cell epitope (DT T-cell epitope).